ProTrans' potential is discussed with professors in diabetes and stem cells

Report this content

NextCell Pharma AB (“NextCell”) NextCell Pharma AB (“NextCell”) has published a scientific presentation where the relevance of the results from the clinical trials with ProTrans for treatment of type 1 diabetes was discussed. Independent diabetes and cell therapy experts have been asked to comment on the previously published study results and NextCell's strategy for the treatment of autoimmune diabetes.

In September, NextCell Pharma published positive results in its Phase II trial, ProTrans-2. Patients treated with a single dose ProTrans showed a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).

Daniel J. Weiss, professor at the University of Vermont, will give an introduction to mesenchymal stem cells and their potential and explain the importance of the study results. Further, Mona Landin-Olsson, professor of endocrinology and diabetes at Lund University, will elaborate on ProTrans’ clinical relevance and the value of preserving patients’ endogenous insulin productionNext. Then, NextCell's CEO, Mathias Svahn, will present the roadmap forward for ProTrans.

The presentation can be streamed via the link below:

Stay up to date with the latest development in NextCell Pharma




For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Phone: 08-735 5595




About NextCell Pharma AB

NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia's largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.

FNCA Sweden AB is assigned as Certified Adviser, 08-528 00 399,


Dokument & länkar